Arsenic Trioxide in Treating Young Patients With Refractory Leukemia or Lymphoma
Phase 1 Completed
Arsenic Trioxide in Treating Patients With Recurrent or Refractory Acute Leukemia, Chronic Myeloide Leukemia, Myelodysplasia, Lymphoma, or Myeloma
Phase 2 Unknown
60 enrolled
Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
Phase 2/3 Completed
2,000 enrolled
Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma
Phase 2 Withdrawn
Arsenic Trioxide in Treating Men With Germ Cell Cancer
Phase 2 Completed
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Chronic Myelogenous Leukemia
Phase 2 Completed
Arsenic Trioxide in Treating Patients With Stage IVB or Recurrent Cervical Cancer
Phase 2 Completed
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Phase 2 Completed
Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia
Phase 3 Completed
420 enrolled
Arsenic Trioxide in Treating Patients With Urothelial Cancer
Phase 2 Completed
35 enrolled
Arsenic Trioxide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
Phase 1 Completed
30 enrolled
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia
Phase NA Terminated
25 enrolled
Arsenic Trioxide in Treating Patients With Advanced Cancer of the Esophagus or Gastroesophageal Junction
Phase 2 Terminated
50 enrolled